Does glutaraldehyde erythropoietin protect kidney in ischaemia/reperfusion injury without increasing red blood cell production?
Herein, we describe a novel lysine-modified rHuEPO, glutaradehyde-EPO (GEPO), obtained from a simple reaction. This derivative has no erythropoietic properties but retains cell-protective characteristics both in vitro and in vivo, with promise for future use as an adjunctive treatment of kidney disease.
Preoperative dipyridamole thallium-201 myocardial perfusion scans were ineffective in predicting postoperative cardiac complications in AAA patients. These results suggest that the routine use of these tests for preoperative screening of patients undergoing AAA repair may not be warranted.